eMedicine Specialties > Obstetrics and Gynecology > Gynecologic Surgery
Pelvic Exenteration: Follow-up
Updated: Dec 22, 2008
Outcome and Prognosis
Reported 5-year survival rates after pelvic exenteration range from 23-61%. The most common site of recurrence is the pelvis. Poor prognostic factors associated with recurrence after exenteration include tumor size greater than 3 cm, pelvic sidewall or resection margin involvement, nodal metastasis, and time interval of less than 1 year from prior radiation treatment.
Future and Controversies
Controversy continues regarding the appropriate selection of patients for exenteration and the use of IORT, preexenteration chemotherapy, concomitant continent urinary diversion, and low rectal anastomosis.
More on Pelvic Exenteration |
| Overview: Pelvic Exenteration |
| Workup: Pelvic Exenteration |
| Treatment: Pelvic Exenteration |
Follow-up: Pelvic Exenteration |
| References |
| « Previous Page |
References
Brunschwig A. Complete excision of the pelvic viscera for advanced carcinoma. Cancer. 1948;1:177.
Eifel P, Berek JS, Thigpen JT. Cancer of the cervix, vagina and vulva. In: Cancer Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 1997:1433-1478.
Hatch KD, Gelder MS, Soong SJ, et al. Pelvic exenteration with low rectal anastomosis: survival, complications, and prognostic factors. Gynecol Oncol. Sep 1990;38(3):462-7. [Medline].
Husain A, Curtin J, Brown C, et al. Continent urinary diversion and low-rectal anastomosis in patients undergoing exenterative procedures for recurrent gynecologic malignancies. Gynecol Oncol. Aug 2000;78(2):208-11. [Medline].
Miller B, Morris M, Rutledge F, et al. Aborted exenterative procedures in recurrent cervical cancer. Gynecol Oncol. Jul 1993;50(1):94-9. [Medline].
Morley GW, Hopkins MP, Lindenauer SM, Roberts JA. Pelvic exenteration, University of Michigan: 100 patients at 5 years. Obstet Gynecol. Dec 1989;74(6):934-43. [Medline].
Morrow CP, Curtin JP. Surgery for cervical neoplasia. In: Gynecologic Cancer Surgery. First ed. Churchill Livingstone; 1996.
Penalver MA, Barreau G, Sevin BU, Averette HE. Surgery for the treatment of locally recurrent disease. J Natl Cancer Inst Monogr. 1996;(21):117-22. [Medline].
Penalver MA, Angioli R, Mirhashemi R, Malik R. Management of early and late complications of ileocolonic continent urinary reservoir (Miami pouch). Gynecol Oncol. Jun 1998;69(3):185-91. [Medline].
Plante M, Roy M. The use of operative laparoscopy in determining eligibility for pelvic exenteration in patients with recurrent cervical cancer. Gynecol Oncol. Dec 1995;59(3):401-4. [Medline].
Rose PG, Blessing JA, Gershenson DM, et al. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. Sep 1999;17(9):2676-80. [Medline].
Rutledge FN, Smith JP, Wharton JT, O'Quinn AG. Pelvic exenteration: analysis of 296 patients. Am J Obstet Gynecol. Dec 15 1977;129(8):881-92. [Medline].
Stehman FB, Perez CA, Kurman RJ. Uterine cervix. In: Principles and Practice of Gynecologic Oncology. 3rd ed. Lippincott Williams & Wilkins; 2000:841-918.
Sugiyama T, Yakushiji M, Noda K, et al. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology. 2000;58(1):31-7. [Medline].
Höckel M. Laterally extended endopelvic resection. Novel surgical treatment of locally recurrent cervical carcinoma involving the pelvic side wall. Gynecol Oncol. Nov 2003;91(2):369-77. [Medline].
Goldberg GL, Sukumvanich P, Einstein MH, Smith HO, Anderson PS, Fields AL. Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol. May 2006;101(2):261-8. [Medline].
Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. Jul 20 2005;23(21):4626-33. [Medline].
Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, Chi DS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol. Jul 2007;106(1):177-80. [Medline].
Tran PT, Su Z, Hara W, Husain A, Teng N, Kapp DS. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys. Oct 1 2007;69(2):504-11. [Medline].
Further Reading
Keywords
pelvic exenteration, anterior exenteration, posterior exenteration, total exenteration, radical resection, supralevator exenteration, infralevator exenteration, vaginectomy, urethrectomy cervical cancer, vaginal cancer, vulvar cancer, uterine cancer, chemotherapy, intraoperative radiation therapy, IORT, ovarian cancer, cervical cancer, squamous cell carcinoma, adenocarcinomas of the cervix, rectal anastomosis, urinary diversion, vaginal reconstruction
Follow-up: Pelvic Exenteration